Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study

被引：0
|
作者：
Olivier Cussenot
Jean-Nicolas Cornu
Sarah J. Drouin
Pierre Mozer
Christophe Egrot
Christophe Vaessen
François Haab
Marc-Olivier Bitker
Morgan Rouprêt
机构：
[1] UPMC Univ Paris 06,Institut Universitaire de Cancérologie
[2] GRC-05,Academic Department of Urology
[3] ONCOTYPE-Uro,Academic Department of Urology
[4] Pitié-Salpétrière Hospital (Assistance Publique—Hôpitaux de Paris),undefined
[5] Tenon Hospital (Assistance Publique—Hôpitaux de Paris),undefined
来源：
World Journal of Urology | 2014年 / 32卷
关键词：
PSA; Androgen deprivation therapy; Prostate cancer; Chemoprevention;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：545 / 550
页数：5
相关论文
共 24 条
  • [1] Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study
    Cussenot, Olivier
    Cornu, Jean-Nicolas
    Drouin, Sarah J.
    Mozer, Pierre
    Egrot, Christophe
    Vaessen, Christophe
    Haab, Francois
    Bitker, Marc-Olivier
    Roupret, Morgan
    WORLD JOURNAL OF UROLOGY, 2014, 32 (02) : 545 - 550
  • [2] Comment on "Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot study"
    de la Taille, A.
    WORLD JOURNAL OF UROLOGY, 2014, 32 (06) : 1625 - 1626
  • [3] Comment on “Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot study”
    A. de la Taille
    World Journal of Urology, 2014, 32 : 1625 - 1626
  • [4] Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study
    van den Bergh, Roderick C. N.
    Vasarainen, Hanna
    van der Poel, Henk G.
    Vis-Maters, Jenneke J.
    Rietbergen, John B.
    Pickles, Tom
    Cornel, Erik B.
    Valdagni, Riccardo
    Jaspars, Joris J.
    van der Hoeven, John
    Staerman, Frederic
    Oomens, Eric H. G. M.
    Rannikko, Antti
    Roemeling, Stijn
    Steyerberg, Ewout W.
    Roobol, Monique J.
    Schroder, Fritz H.
    Bangma, Chris H.
    BJU INTERNATIONAL, 2010, 105 (07) : 956 - 962
  • [5] Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08
    Voog, Justin C.
    Paulus, Rebecca
    Shipley, William U.
    Smith, Matthew R.
    McGowan, David G.
    Jones, Christopher U.
    Bahary, Jean-Paul
    Zeitzer, Kenneth L.
    Souhami, Luis
    Leibenhaut, Mark H.
    Rotman, Marvin
    Husain, Siraj M.
    Gore, Elizabeth
    Raben, Adam
    Chafe, Susan
    Sandler, Howard M.
    Efstathiou, Jason A.
    EUROPEAN UROLOGY, 2016, 69 (02) : 204 - 210
  • [6] A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study
    Barrett, Tristan
    Pacey, Simon
    Leonard, Kelly
    Wulff, Jerome
    Funingana, Ionut-Gabriel
    Gnanapragasam, Vincent
    EUROPEAN UROLOGY OPEN SCIENCE, 2022, 38 : 17 - 24
  • [7] Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer
    Douglas G. McNeel
    Heath A. Smith
    Jens C. Eickhoff
    Joshua M. Lang
    Mary Jane Staab
    George Wilding
    Glenn Liu
    Cancer Immunology, Immunotherapy, 2012, 61 : 1137 - 1147
  • [8] Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer
    McNeel, Douglas G.
    Smith, Heath A.
    Eickhoff, Jens C.
    Lang, Joshua M.
    Staab, Mary Jane
    Wilding, George
    Liu, Glenn
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (07) : 1137 - 1147
  • [9] Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer
    Mellado, B.
    Font, A.
    Alcaraz, A.
    Aparicio, L. A.
    Veiga, F. J. G.
    Areal, J.
    Gallardo, E.
    Hannaoui, N.
    Lorenzo, J. R. M.
    Sousa, A.
    Fernandez, P. L.
    Gascon, P.
    BRITISH JOURNAL OF CANCER, 2009, 101 (08) : 1248 - 1252
  • [10] Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer
    B Mellado
    A Font
    A Alcaraz
    L A Aparicio
    F J G Veiga
    J Areal
    E Gallardo
    N Hannaoui
    J R M Lorenzo
    A Sousa
    P L Fernandez
    P Gascon
    British Journal of Cancer, 2009, 101 : 1248 - 1252
123